---
title: "Fudan Zhangjiang Invests RMB150 Million in Low-Risk Bank of China Structured Deposit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291528523.md"
description: "Shanghai Fudan Zhangjiang Bio Pharmaceutical (HK:1349) invested RMB150 million in a low-risk, principal-guaranteed structured deposit with Bank of China. The 90-day product offers a floating annualized return of 0.35%-1.65%, linked to USD/CAD rates. This transaction, classified as a disclosable transaction under Hong Kong Listing Rules, aims to optimize returns on idle proceeds from A-share issuance while maintaining capital safety."
datetime: "2026-07-02T09:40:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291528523.md)
  - [en](https://longbridge.com/en/news/291528523.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291528523.md)
generator: "portal-rs"
---

# Fudan Zhangjiang Invests RMB150 Million in Low-Risk Bank of China Structured Deposit

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has shared an update.

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co has subscribed to a principal-guaranteed structured deposit product from Bank of China, investing RMB150 million of temporarily idle proceeds raised from its public A-share issuance. The 90-day deposit, assessed by the bank as low-risk, offers a floating annualized return between 0.3500% and 1.6500%, linked to movements in the USD/CAD central parity rate.

Because one or more applicable percentage ratios under Hong Kong Listing Rules exceed 5% but remain below 25%, the arrangement is classified as a disclosable transaction requiring reporting and public announcement but not shareholder approval. The move underscores the company’s effort to enhance returns on surplus funds while maintaining capital safety, reflecting conservative treasury management amid ongoing biopharmaceutical operations.

**More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co**

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co is a Hong Kong-listed biopharmaceutical company focused on developing, manufacturing, and commercializing innovative drug products. It operates in the life sciences sector and funds its activities partly through public issuance of A shares, deploying idle proceeds in low-risk financial instruments to optimize treasury management.

The company positions itself as a research-driven player in the biopharma industry while actively managing liquidity through structured deposit products with major banks.

**Average Trading Volume:** 2,680,614

**Current Market Cap:** HK$772.6M

Learn more about 1349 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [688505.CN](https://longbridge.com/en/quote/688505.CN.md)
- [BACHY.US](https://longbridge.com/en/quote/BACHY.US.md)
- [01349.HK](https://longbridge.com/en/quote/01349.HK.md)
- [601988.CN](https://longbridge.com/en/quote/601988.CN.md)
- [03988.HK](https://longbridge.com/en/quote/03988.HK.md)
- [02388.HK](https://longbridge.com/en/quote/02388.HK.md)

## Related News & Research

- [WeChat Pay HK Launches Shenzhen Departure Tax Refund Service](https://longbridge.com/en/news/297116910.md)
- [Bank of China announces RMB 3.27 dividend for domestic preference shares fourth tranche](https://longbridge.com/en/news/296479628.md)
- [China’s largest five banks report strongest first-half profit since height of property crash](https://longbridge.com/en/news/297322605.md)
- [BANK OF CHINA 1H26 Net Profit Mounts 5.1% to RMB123.59B; Interim DPS RMB0.119](https://longbridge.com/en/news/297295153.md)
- [Bank of China H1 profit rises 4.67% to RMB 132.03 billion; revenue climbs 8.41% to RMB 357.11 billion](https://longbridge.com/en/news/297290026.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**